Literature DB >> 12736970

Risk factors, clinical features and genotype distribution of diagnosed hepatitis C virus infections: a pilot for a sentinel laboratory-based surveillance.

M A Balogun1, H Laurichesse, M E Ramsay, J Sellwood, D Westmoreland, W K Paver, S F Pugh, M Zuckerman, D Pillay, T Wreghitt.   

Abstract

Hepatitis C is a global public health problem. A cross-sectional survey was undertaken to determine the frequency of reported risk factors and possible transmission routes in individuals in whom HCV antibody (anti-HCV) was newly detected. Seven public health laboratories in England and Wales reported persons with positive anti-HCV tests over a three-month period (1st November 1996-31st January 1997). A questionnaire was then sent to the clinician or general practitioner (GP) who requested the test. A total of 320 laboratory reports were received from participating laboratories and 221 (69%) questionnaires were received from clinicians and GPs. Of those patients from whom a questionnaire was received (median age 36 years; males 72.9%, females 23.1%), 86% had one or more risk factors for infection reported by the clinician/GP. Injecting drug use (68%) was the main risk factor reported. Reasons for testing included being in a known risk group (65%), liver disease (19%) and blood donation (1.4%). Of the total responders, 67% were asymptomatic, and of those that had had liver function tests 50% were abnormal. The most prevalent HCV genotypes were 3a and 1a. Risk factors for HCV infection can be identified using a simple postal questionnaire to clinicians/GPs who request patient screening.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12736970

Source DB:  PubMed          Journal:  Commun Dis Public Health        ISSN: 1462-1843


  7 in total

1.  Sentinel laboratory surveillance of hepatitis C antibody testing in England: understanding the epidemiology of HCV infection.

Authors:  L J Brant; M Hurrelle; M A Balogun; P Klapper; F Ahmad; E Boxall; A Hale; V Hollyoak; I B Ibrahim; W Irving; R Meigh; K J Mutton; B C Patel; W K Paver; S Pugh; C Taylor; A J Turner; M E Ramsay
Journal:  Epidemiol Infect       Date:  2006-07-13       Impact factor: 2.451

2.  Hepatitis C virus: laboratory surveillance in England and Wales, 1992-2004.

Authors:  U Gungabissoon; M A Balogun; M E Ramsay
Journal:  Epidemiol Infect       Date:  2006-09-06       Impact factor: 2.451

3.  Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation.

Authors:  Walter Cullen; June Stanley; Deirdre Langton; Yvonne Kelly; Anthony Staines; Gerard Bury
Journal:  Br J Gen Pract       Date:  2006-11       Impact factor: 5.386

4.  Hepatitis C virus genotypes in Serbia and Montenegro: the prevalence and clinical significance.

Authors:  Neda Svirtlih; Dragan Delic; Jasmina Simonovic; Djordje Jevtovic; Ljubisa Dokic; Eleonora Gvozdenovic; Ivan Boricic; Dragic Terzic; Sladjana Pavic; Gorana Neskovic; Sonja Zerjav; Vladimir Urban
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

5.  Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006.

Authors:  Francois Roman; Karin Hawotte; Daniel Struck; Anne-Marie Ternes; Jean-Yves Servais; Vic Arendt; Patrick Hoffman; Robert Hemmer; Therese Staub; Carole Seguin-Devaux; Jean-Claude Schmit
Journal:  World J Gastroenterol       Date:  2008-02-28       Impact factor: 5.742

6.  High Prevalence of Hepatitis C virus Among Injection Drug Users in Zhenjiang, Jiangsu, China.

Authors:  Nana Wu; Qinjuan Ge; Qingchuan Feng; Jun Zhang; Xiaoxia Liu; Caihong Sun; Yongkang Xu; Guangli He; Chiyu Zhang
Journal:  Indian J Virol       Date:  2011-06-30

Review 7.  Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention.

Authors:  Lucas Wiessing; Marica Ferri; Bart Grady; Maria Kantzanou; Ida Sperle; Katelyn J Cullen; Angelos Hatzakis; Maria Prins; Peter Vickerman; Jeffrey V Lazarus; Vivian D Hope; Catharina Matheï
Journal:  PLoS One       Date:  2014-07-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.